• Wordpackage: Aucun
  • Institution: INRIA/COMPO, Marseille

Sebastien Benzekry is a scientific research director (DR, PhD, HDR) at Inria, the French institute for applied mathematics, computer science and their applications. He has created in 2021 and since then leads the joint Inria (French national institute for digital science)  – Inserm (French national institute for biomedical research) project-team COMPO (COMPutational pharmacology and clinical Oncology), located at the Center for Research on Cancer of Marseille (Pharmacy faculty, Aix-Marseille University). The objective of his research is to model data arising from (clinical) oncology in order to 1) bring clinical decision tools to enhance therapeutic management, 2) better inform and design clinical trials and 3) test biological hypotheses. To do so, he combines mechanistic models (i.e., simulation models of the pharmaco-patho-physiological processes, also called "digital twins"), and statistical learning through an approach termed 'mechanistic learning'. He has fifteen years of experience in trans-disciplinary projects in oncology. His main topics of research are modeling metastatic development and immuno-oncology, integrating longitudinal data. These are implemented into several open source software.

Dr Benzekry has an initial training in applied mathematics (Ecole Normale Supérieure) followed by a PhD at Aix-Marseille University and a postdoc in the Center for Cancer and Systems Biology, Tufts Univ, Boston, MA.

https://team.inria.fr/compo/

https://www-sop.inria.fr/members/Sebastien.Benzekry/index.html

https://scholar.google.fr/citations?user=xsLpdFAAAAAJ&hl=fr&oi=ao

Cookies user preferences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Analytics
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.
Google Analytics
Accept
Decline
Advertisement
If you accept, the ads on the page will be adapted to your preferences.
Google Ad
Accept
Decline
Save